Although prostaglandin E 2 (PGE 2 ) has been shown by pharmacologic and genetic studies to be important in skin cancer, the molecular mechanism(s) by which it contributes to tumor growth is not well understood. In this study, we investigated the mechanisms by which PGE 2 stimulates murine keratinocyte proliferation using in vitro and in vivo models. In primary mouse keratinocyte cultures, PGE 2 activated the epidermal growth factor receptor (EGFR) and its downstream signaling pathways as well as increased cyclic AMP (cAMP) production and activated the cAMP response element binding protein (CREB). EGFR activation was not significantly inhibited by pretreatment with a c-src inhibitor (PP2), nor by a protein kinase A inhibitor (H-89). However, PGE 2 -stimulated extracellularly regulated kinase 1/2 (ERK1/2) activation was completely blocked by EGFR, ERK1/2, and phosphatidylinositol 3-kinase (PI3K) pathway inhibitors. In addition, these inhibitors attenuated the PGE 2 -induced proliferation, nuclear factor-KB, activator protein-1 (AP-1), and CREB binding to the promoter regions of the cyclin D1 and vascular endothelial growth factor (VEGF) genes and expression of cyclin D1 and VEGF in primary mouse keratinocytes. Similarly, in vivo, we found that WT mice treated with PGE 2 and untreated cyclooxygenase-2 -overexpressing transgenic mice had higher levels of cell proliferation and expression of cyclin D1 and VEGF, as well as higher levels of activated EGFR, nuclear factor-KB, AP-1, and CREB, than vehicle-treated WT mice. Our findings provide evidence for a link between cyclooxygenase-2 overexpression and EGFR-, ERK-, PI3K-, cAMP-mediated cell proliferation, and the tumor-promoting activity of PGE 2 in mouse skin.
Introduction
Prostaglandins have been associated with many normal and pathophysiologic responses, including ovulation, vessel contraction/relaxation, renal filtration, gastrointestinal protection, angiogenesis, increased proliferation, tumorigenesis, and immune suppression (1) (2) (3) (4) . Prostaglandin production is regulated by the enzyme cyclooxygenase (COX), which catalyzes the conversion of arachidonic acid to PGH 2 through a two-step process involving distinct cyclooxygenase and peroxidase activities (5) . Two isoforms of COX have been identified (i.e., COX-1 and COX-2). COX-1 is constitutively expressed in most tissues and cell types and mediates tissue homeostasis, whereas COX-2 is induced by a variety of mitogenic and inflammatory factors and is highly expressed in most epithelial cancers including those of skin (6) .
In the context of epidermal keratinocytes, there are a number of observations suggesting that prostaglandin E 2 (PGE 2 ) is a versatile eicosanoid that plays a key role in normal skin homeostasis, although it can also act as a tumor promoter, controlling many of the behaviors typical of cancer cells (7) (8) (9) . Moreover, several studies showed that PGE 2 production is induced by numerous stimuli, including known skin tumor promoters such as UV irradiation (10, 11 ) and 12-O-tetradecanoylphorbol-13-acetate (TPA; refs. 12, 13). In addition, it has been suggested that at least some of the tumor-promoting effects of these agents are mediated by stimulation of PGE 2 production (1, 7, 9, 13, 14) . The requirement of high PGE 2 levels for skin tumor development is further suggested by studies in which inhibitors of COX had strong chemopreventive activity (15) . In addition, strong support for a role of prostaglandins in skin tumor promotion comes from initiation-promotion studies using COX-1 -and COX-2 -deficient mice, in which a 70% to 80% reduction in papilloma number, compared with wild-type (WT) mice was observed in each isoform-deficient mouse (16) . In support of the above observations, Rundhaug et al. (17) found that endogenous PGE 2 in K14.COX-2 transgenic mice has tumor-promoting activity. However, the role of PGE 2 in keratinocyte function is still not entirely clear. Although prostaglandins have not been shown to be involved in normal murine keratinocyte proliferation in vivo, PGE 2 was found to be a required co-mitogen for phorbol ester -elicited hyperproliferation and after mechanical wounding (13, 18) . In vitro, however, several studies suggested an involvement of prostaglandins even in unstimulated proliferation. In human keratinocytes, a correlation between endogenous PGE 2 and DNA synthesis was observed. Inhibition of proliferation by indomethacin can be overcome by exogenous addition of PGE 2 , strongly suggesting that PGE 2 is a growth-promoting factor for the epidermis (19, 20) . Collectively, these studies suggest that keratinocyte proliferation is highly regulated by prostaglandins; an understanding of its regulation could potentially offer targets for the prevention of pathologies.
PGE 2 exerts its actions either in an autocrine or paracrine fashion via binding to four E-prostanoid receptor subtypes, termed EP1, EP2, EP3, and EP4, that differ in ligand-binding affinity, tissue distribution, and coupling to intracellular signal transduction pathways (21) . All four PGE 2 receptors were found to be present in normal human and mouse epidermis (22, 23) ; however, to date, there is limited information on the role of the E-prostanoid receptors, and/or receptor-mediated signal transduction pathways involved in keratinocyte proliferation. Recently, we reported that the EP2 receptor, but not the EP3 receptor, plays a significant role in the protumorigenic action of TPA in skin tumor development (23) . Additionally, it has been shown that COX-2 and the PGE 2 receptors, EP1, EP2, and/or EP4, are important for UV-induced skin carcinogenesis (reviewed in ref. 24) . Another study showed that the EP2 receptor promotes squamous cell carcinoma development through the epidermal growth factor receptor (EGFR)/inducible nitric oxide synthase/extracellular signal-regulated kinase 1/2 (ERK1/2) pathways (25) . However, to date, there are no reports showing a direct effect of PGE 2 on keratinocyte proliferation.
Skin cancer is the most common form of cancer and the incidence is increasing steadily. The average increase in new skin cancer cases has been around 3% to 8% per year since the 1960s, with approximately 1 million new cases diagnosed each year in the United States (26) . Thus, improving our understanding of effective skin cancer chemoprevention can have a large effect on health. Work to date has focused on inhibition of cyclooxygenases as an approach to skin cancer chemoprevention because selective COX-2 inhibition can suppress tumor formation in chronically UV-irradiated mice (15) . However, recent studies in humans have shown that treatment with selective COX-2 inhibitors increases the risks of cardiovascular events (27) . Thus, a better understanding of the consequences of PGE 2 -mediated signaling in skin is needed to refine our ability to predict the risks and benefits of chemoprevention targeted to PGE 2 -mediated cellular functions.
The current study was designed to look at the effect of PGE 2 on keratinocyte proliferation using in vitro and in vivo mouse models and to delineate the definitive mechanism(s) through which PGE 2 mediates these effects. Here, we report that in primary mouse keratinocytes (PMK), PGE 2 rapidly induces phosphorylation of EGFR, as well as activation of c-src, Ras, mitogen-activated protein kinases (MAPK) and phosphatidylinositol-3-kinase (PI3K)/Akt pathways. As expected, we found that PGE 2 can also activate the cyclic AMP (cAMP)/protein kinase A (PKA) pathway. Both the EGFR/MAPK and cAMP/ PKA pathways are needed for PGE 2 -elicited cell proliferation. We further show that PGE 2 increased binding of cAMP response element binding protein (CREB), activator protein-1 (AP-1), and nuclear factor-nB (NF-nB) to the promoter regions of the cell growth regulatory genes, cyclin D1 and vascular endothelial growth factor (VEGF), and induced the expression of these genes. These findings suggest that PGE 2 may promote the growth of tumors by activating several signaling pathways that lead to the expression of genes involved in proliferation and other tumor promotion processes.
Results

PGE 2 Induces Keratinocyte Proliferation In vitro
Because PGE 2 -induced keratinocyte proliferation may be one of the key mechanisms by which PGE 2 promotes skin tumorigenesis, we investigated whether PGE 2 would affect the proliferation of PMKs. As shown in Fig. 1A , DNA synthesis was stimulated in a dose-response manner following 20 h of PGE 2 treatment. PGE 2 , at 1, 10, and 30 Amol/L, increased DNA synthesis by 2.2-, 4.5-, and 7.6-fold respectively (Fig. 1A) .
PGE 2 Activates EGFR-Ras-MAPK and Akt Signaling Pathways
Recently, there has been a concerted effort to understand the signaling cascades from G-protein coupled receptors to events typically thought to be associated with growth factor stimulation, such as the PI3K/Akt and Ras/Raf/MEK pathways (28) (29) (30) . Here, we investigated the effect of PGE 2 on activation of EGFR, Ras, Akt, c-src, and MAPKs. When PMKs were treated with 10 Amol/L PGE 2 , we found that EGFR (Tyr 1173 ) and c-src (Tyr 416 ) were activated 2.5-and 4.8-fold over vehicle-treated cultures after 5 min, respectively (Fig. 1B) . To show that PGE 2 can induce endogenous Ras (WT) activity, PMKs were treated with PGE 2 for various times following serum starvation and subjected to a Ras activity assay. We found that PGE 2 increased Ras activation 2.8-fold over control; all the samples exhibited similar levels of total Ras protein (Fig. 1C ). In addition, we found that an EGFR-specific inhibitor, AG1478, and c-src inhibitor, PP2, blocked PGE 2 -induced Ras activity, which suggests that EGFR and c-src are upstream of Ras (Fig. 1C) .
Because the MAPK cascade is downstream from EGFR and Ras, we next examined whether PGE 2 could activate MAPK signaling (Fig. 1D ). PMKs were treated with PGE 2 , followed by Western blotting with antibodies that recognize the phosphorylated (activated) forms of ERK1/2, p38, and Junamino-terminal kinase (JNK)/stress-activated protein kinase (SAPK). As shown in Fig. 1D , PGE 2 enhanced phosphorylation of ERK1/2 (3.5-fold) 5 min after treatment, but there was no change in the phosphorylation of p38 or JNK/SAPK, other MAPK family members in primary keratinocytes (data not shown). We further assessed the effect of PGE 2 on another signaling molecule downstream of EGFR, Akt. As shown in Fig. 1D (31) . These results show that PGE 2 also stimulated Akt activation in a timedependent manner.
To determine the relative sequence of PGE 2 signaling, the effect of pathway-specific inhibitors on the activation of various potential intermediates were examined. Preincubation of PMKs with the EGFR kinase inhibitor, AG1478, caused a complete inhibition of PGE 2 -induced activation of Akt, whereas the PI3K inhibitor, wortmannin, completely abrogated both basal and PGE 2 -induced activation of Akt ( Fig. 2A) . Both of these results were not unexpected as EGFR is known to activate PI3K, and PI3K is upstream of Akt. Similarly, the ERK inhibitor, PD98059, completely blocked basal and PGE 2 -induced activation of ERK1/2 (Fig. 2B) . On the other hand, wortmannin as well as AG1478 only partially blocked PGE 2 -induced ERK1/2 activation, which may be the result of their strong inhibition of basal ERK1/2 levels (Fig. 2B) . Taken together, these results suggest that the PGE 2 -induced activation of Akt is mediated via activation of EGFR, whereas ERK1/2 may be activated in part through an EGFR-independent mechanism.
Effect of c-src and PKA Inhibitors on Activation of EGFR Although several reports have shown that activation of the c-src family of nonreceptor tyrosine kinases is involved in G-protein coupled receptor -mediated signaling, the position of c-src in signaling pathways remains unknown (32) . We examined the effect of PP2 (c-src inhibitor) and AG1478 on PGE 2 -induced phosphorylation of the EGFR. As shown in Fig. 2C , pretreatment of PMKs with PP2 does not significantly affect PGE 2 -induced phosphorylation of EGFR, whereas pretreatment with AG1478 blocked the PGE 2 -induced phosphorylation of the EGFR as expected. Interestingly, pretreatment of PMKs with either EGFR or c-src inhibitor strongly inhibited the basal level of c-src phosphorylation, suggesting that the inhibition of PGE 2 -induced c-src activation by these inhibitors is probably the result of reduced basal levels (Fig. 2D) . Moreover, the observation that PGE 2 significantly activates c-src (Fig. 1B) , whereas c-src inhibition has little effect on EGFR activation (Fig. 2C) , suggests that c-src is downstream of EGFR. There was no change in EGFR activation with the PKA inhibitor, H-89 (Fig. 2C) .
PGE 2 -Stimulated cAMP Formation and Phosphorylation of CREB In vitro PGE 2 activates different signaling pathways depending on the receptor to which it binds. Our recent findings (33) show that EP2 is a major PGE 2 receptor, which upon ligand binding activates adenylate cyclase with subsequent synthesis of cAMP and activation of PKA. To determine whether PGE 2 increased cAMP production and thereby activated the PKA pathway and CREB-mediated transcription in our experiments, we measured cAMP levels in cultured PMKs following PGE 2 treatment. The concentrations of cAMP were significantly higher (2.5-fold) in cells after PGE 2 treatment than in cells without exogenous PGE 2 (Fig. 2E ). As expected, PGE 2 -induced cAMP production was inhibited in keratinocytes treated with SQ 22,536, an adenylate cyclase inhibitor. Next, we examined the effect of Because we observed that PGE 2 can induce multiple mitogenic signaling pathways, we next assessed the effect of PGE 2 and some pathway-specific inhibitors on the DNAbinding activity of CREB, NF-nB, and AP-1. As shown in Fig. 3A , PGE 2 enhanced CREB DNA-binding activity, whereas AG1478, PD98059, and wortmannin inhibited PGE 2 -induced DNA-binding activity significantly. Surprisingly, we found that there was much lower inhibition with H-89 (PKA inhibitor) compared with AG1478 and wortmannin. Similar results were seen with AP-1 ( Fig. 3B ) and with NF-nB (Fig. 3C) binding to DNA.
Role of EGFR, MAPK, PI3K, and cAMP/PKA Signaling Pathways on PGE 2 -Induced Cell Proliferation
Our above findings suggest that PGE 2 can activate EGFR, MAPK, PI3K, and cAMP/PKA signaling pathways and that it can induce cell proliferation in a dose-dependent manner. Next, to determine whether these signaling pathways are responsible for PGE 2 -induced cell proliferation, cultures of PMKs were incubated with various signaling inhibitors for 30 min before PGE 2 treatment and DNA synthesis was measured. As shown in Fig. 3D , the EGFR inhibitor AG1478 completely blocked PGE 2 -induced cell proliferation. On the other hand, ERK1/2, PKA, and PI3K inhibitors also blocked PGE 2 -induced cell proliferation, but not to the same extent as the EGFR inhibitor. Here, it is important to note that the PKA inhibitor H-89 does not inhibit the phosphorylation of EGFR (Fig. 2C ), but can partially block PGE 2 -induced cell proliferation.
PGE 2 -Induced Cyclin D1 and VEGF Promoter Activity and mRNA Expression in PMKs
To determine whether cyclin D1 and/or VEGF genes are involved in PGE 2 -induced keratinocyte proliferation, as shown in Fig. 4A and B, PMKs were transiently transfected with luciferase reporter constructs containing cyclin D1 and VEGF promoters. Treatment with PGE 2 for 24 h enhanced cyclin D1 as well as VEGF promoter activities. Next, we looked at the effect of PGE 2 on mRNA levels of cyclin D1 and VEGF in vitro and found maximum expression of cyclin D1 (12-fold induction) and VEGF (5-fold induction) after 24 h and 12 to 18 h of PGE 2 treatment, respectively (Fig. 4C) .
Role of EGFR, MAPK, PI3K, and cAMP/PKA Signaling Pathways on PGE 2 Induction of Cyclin D1 and VEGF To further elucidate the molecular mechanism by which PGE 2 enhanced cyclin D1 and VEGF transcription and mRNA expression, we investigated the effect of EGFR, ERK1/2, PI3K, and PKA inhibitors on PGE 2 -induced cyclin D1 and VEGF promoter activities and mRNA expression. We incubated PMKs in the presence of EGFR, ERK1/2, PI3K, and PKA inhibitors for 30 min before PGE 2 treatment. As shown in Fig. 4D and E, the pharmacologic inhibitors significantly reduced PGE 2 -induced cyclin D1 and VEGF promoter activities. Next, we were interested in the effect of these pathway inhibitors on PGE 2 -induced expression of cyclin D1 and VEGF mRNA. As shown in Fig. 4F (top) , cyclin D1 mRNA levels were significantly decreased with inhibition of either EGFR, PKA, ERK, or PI3K. The levels of VEGF mRNA (Fig. 4F, bottom) were also decreased significantly, although not as completely as cyclin D1 mRNA levels.
Binding of CREB, AP-1, and NF-jB to the Promoter Region of Cyclin D1 and VEGF
To provide further evidence that CREB, NF-nB, or AP-1 regulate cyclin D1 and VEGF promoter activity after PGE 2 treatment, and to show that the interaction of CREB, NF-nB, and AP-1 with endogenous cyclin D1 and VEGF promoters occurs in intact cells, we did chromatin immunoprecipitation (ChIP) assays. The ChIP data revealed that CREB, NF-nB, and AP-1 physically bound to the promoter region of cyclin D1 and that binding was significantly enhanced by PGE 2 treatment (Fig. 5A) . Similar results were found for CREB, NF-nB, and AP-1 binding to the promoter region of VEGF (Fig. 5B) . Tumor necrosis factor-a and forskolin were used as positive controls in this experiment because tumor necrosis factor-a is a strong inducer of NF-nB and AP-1 activity (34) and forskolin activates adenylate cyclase, which results in activation of CREB (35) .
PGE 2 Can Induce Cell Proliferation In vivo
To study the role of PGE 2 in the proliferation of mouse keratinocytes in vivo, we immunostained skin sections for Ki-67. WT mice were topically treated with either vehicle or PGE 2 (30 Ag/mouse) for 18 h. To determine if endogenous PGE 2 could also stimulate keratinocyte proliferation in vivo, we also immunostained skin sections from vehicle-treated K14.COX-2 transgenic mice. These transgenic mice overexpress COX-2 and have f2-fold elevated levels of PGE 2 in the epidermis (36) . Our results showed that the number of Ki-67 -positive epidermal cells in PGE 2 -treated WT mice and in vehicletreated K14.COX-2 transgenic mice was significantly higher than in vehicle-treated WT mice (Fig. 6A) ; that is, 18.3% cells were Ki-67 positive in vehicle-treated WT mice compared with 30.2% and 35.4% Ki-67 -positive epidermal cells in PGE 2 -treated WT and vehicle-treated COX-2 transgenic mice, respectively.
Activation of EGFR, c-src, CREB, MAPKs, and Akt in K14.COX-2 Transgenic and WT Mouse Skin
To determine whether the PGE 2 -elicited signaling events and proliferative outcome occur in vivo either after exogenous PGE 2 treatment or by high endogenous levels of PGE 2 , WT mice (3 in each group) were treated with either vehicle or PGE 2 and 3 K14.COX-2 transgenic mice were treated with vehicle only. For Western blotting, epidermal lysates of each group of three mice were pooled together. As shown in Fig. 6B , EGFR was found to be highly phosphorylated in epidermal lysates from both PGE 2 -treated WT mice and vehicle-treated K14.COX-2 mice. Likewise, c-src and CREB were similarly highly phosphorylated in both the PGE 2 -treated WT mice and vehicle-treated COX-2 transgenic mice (Fig. 6B) . The MAPKs, ERK1/2, p38, and JNK/SAPK were also highly phosphorylated in PGE 2 -treated WT mice, and to a somewhat lesser extent in vehicle-treated K14.COX-2 transgenic mice (Fig. 6B) . Representative data from at least two independent experiments using triplicates for each treatment group. Columns, means; bars, SD. *, P < 0.05, significant when compared with the vehicle treatment group. C. Effects of PGE 2 on mRNA expression of cyclin D1 and VEGF. PMKs were treated with PGE 2 (10 Amol/L) for the indicated time points. RNA was isolated from the PMKs and Northern blots were hybridized sequentially with cDNA probes for cyclin D1, VEGF, and GAPDH (loading control). Quantitation of the intensities of the bands was determined by densitometry and the ratios of cyclin D1 and VEGF to GAPDH are shown above each lane. Specific inhibitors block PGE 2 induction of cyclin D1 (D) and VEGF (E) promoter activities. Cells were pretreated with inhibitors for 30 min before the PGE 2 (10 Amol/L) treatment. Data are presented as fold induction of relative luciferase activity. Representative data from at least two independent experiments using triplicates for each treatment group. Columns, means; bars, SD. *, P < 0.05, significant when compared with PGE 2 -treated group. F. Effect of specific inhibitors on PGE 2 -induced mRNA expression of cyclin D1 and VEGF. PMKs were pretreated with inhibitors for 30 min before the PGE 2 (10 Amol/L) treatment for 18 h. RNA was isolated and probed as in C. Intensities of the bands were determined by densitometry and the ratios of cyclin D1 and VEGF to GAPDH are shown above each lane.
PGE 2 Can Induce Cyclin D1 and VEGF In vivo
Next, we looked at the effect of PGE 2 on cyclin D1 and VEGF mRNA in vivo and found maximum expression of cyclin D1 (3.5-fold; Fig. 6C, top) , and VEGF (1.8-fold, bottom), 12 h after PGE 2 treatment in WT mice. By comparison, the mRNA levels of cyclin D1 and VEGF were even higher in vehicletreated K14.COX-2 mice than in PGE 2 -treated WT mice (Fig. 6C) . Taken together, these results support our in vitro studies and show the similar consequence of PGE 2 -induced proliferation and signaling in vivo.
Discussion PGE 2 is a major product of prostanoid metabolism in keratinocytes in intact skin as well as in culture, with increased levels observed in cutaneous neoplasms (2, 9) . Prostaglandin signaling is likely to be important in regulating normal epidermal growth as well as the hyperplastic response to epidermal inflammation (1, 8, 37) . Moreover, in cultures of human keratinocytes, a correlation between endogenous PGE 2 production and DNA synthesis was observed and inhibition of proliferation by indomethacin was countered by adding back PGE 2 (19, 20) . In addition, we have shown that endogenous PGE 2 in K14.COX-2 transgenic mice has tumor-promoting activity (17) . Nonetheless, to date, prostaglandins have not been shown to be involved in normal murine keratinocyte proliferation in vivo and the definitive mechanism(s) through which PGE 2 mediates these effects also remains unknown. Our current study provides evidence that exogenous PGE 2 can increase keratinocyte proliferation in cultures of PMKs and that exogenous, as well as endogenous, PGE 2 is able to induce keratinocyte proliferation in vivo. Our data suggest the mechanisms involve PGE 2 -induced phosphorylation of EGFR and activation of Ras-MAPKs, PI3K/Akt, and cAMP/PKA signaling pathways. Furthermore, our data revealed that PGE 2 increased binding of CREB, NF-nB, and AP-1 to the promoters of cyclin D1 and VEGF.
Several investigators have found that EGFR signaling is a major regulator of cell proliferation and survival in many epithelial cell types. Activation of EGFR and H-ras in the early stages of skin carcinogenesis may contribute to tumor development (38) . Chen et al. (39) showed that the signaling pathway activated by EGFR is very important in modulating cell proliferation and is a necessary component for TPAinduced signal transduction associated with skin tumor promotion. In addition, egfr-deficient cells and potent inhibitors of EGFR, PD153035, and AG1478 blocked TPA-induced phosphorylation of ERKs, AP-1 activity, and cell transformation (39) . Similarly, we also found that PGE 2 caused an activation of EGFR in PMKs and in mouse skin. In addition, we also found that the EGFR inhibitor, AG1478, blocked PGE 2 -induced PMK proliferation. Thus, our data indicate that EGFR signaling is involved in PGE 2 -induced normal PMK proliferation in culture and in mouse skin. Chromatin fragments were immunoprecipitated (IP ) with antibodies (Ab) against phospho-CREB, c-Fos, c-Jun, p65 of NF-nB, or with control rabbit immunoglobulin. Chromatin-bound DNA and input (original nuclear extract) was subjected to PCR amplification using primers specific for promoter regions of cyclin D1 (A) and VEGF (B). Tumor necrosis factor-a and forskolin were used as positive controls for induction of AP-1, NF-nB, and CREB, respectively.
MAPKs constitute a superfamily of proteins that include ERK1/2, JNK1/2, and p38 kinases that play a central role in coordinating the transmission of various types of signals to the nucleus (40) . Several reports suggest that aberrant activation of MAPKs play an important role in skin carcinogenesis. For example, elevated ERK1/2 activity has been detected in TPApromoted mouse skin (41) . In another study, TPA-promoted tumorigenesis was reduced in ERK-1 knockout mice (42) . JNK and p38 also may play a role in carcinogenesis, acting as either tumor suppressors or as pro-oncogenic signaling molecules (43).
Although JNK, p38, and ERK1/2 are often activated by different signals, these three MAPKs can modulate AP-1 activity (44). Moreover, ERK1/2 and p38 proteins have been shown to modulate NF-nB activation (41) . The increased AP-1 and NF-nB activities play a very crucial role in skin carcinogenesis and have been implicated in cell proliferation, apoptosis, adhesion, and inflammatory responses (45) (46) (47) . In addition, the requirement of NF-nB has been shown for TPA-induced transformation of JB6 epidermal cells (48) . Interestingly, our study reveals that ERK1/ 2, p38, and JNK are also activated by PGE 2 in vivo. However, ); and total EGFR, CREB, ERK1/2, p38, Akt, or actin were analyzed by Western blotting. Quantitation of the intensities of the bands shown were determined by densitometry and the relative ratios of phosphorylated forms to total EGFR, total ERK1/2, total p38, total Akt, or actin were normalized to the vehicle-treated samples and are shown above each lane. This experiment was repeated without pooling lysates and gave similar results. C. Effects of exogenous and endogenous PGE 2 on mRNA expression of cyclin D1 and VEGF in vivo . WT mice and K14.COX2 transgenic mice were treated as in B. These three groups of mice were sacrificed at the indicated times after PGE 2 or vehicle treatment. RNA was isolated from the skin and Northern blots were hybridized sequentially with cDNA probes for cyclin D1, VEGF, and GAPDH (loading control). Intensities of the bands were determined by densitometry and the ratios of cyclin D1 and VEGF to GAPDH are shown above each lane. D. A schematic drawing showing the signal transduction pathways mediating PGE 2 -induced primary keratinocyte proliferation.
See the text for details.
in vitro, only ERK1/2, but not p38 or JNK, was activated. The reason for this in vivo/in vitro difference is not clear. Thus, our current results may be significant to PGE 2 -induced tumor promotion in light of a previous report that TPA-and/or UVenhanced PGE 2 synthesis, and activation of MAPKs, NF-nB, and AP-1 are involved in keratinocyte proliferation (39, 46) . However, previously, it was unknown whether MAPKs, AP-1, and NF-nB signaling were important for PGE 2 -induced keratinocyte proliferation and our data suggest that during skin tumor promotion, PGE 2 activates similar mitogenic signaling pathways and likely mediates skin tumor promotion through the same mechanisms as TPA and/or UV.
Multiple intracellular signaling pathways can be activated after prostanoid receptor binding (25, 49, 50) . The different signal transduction pathways induced by PGE 2 seem to depend on the type of cells and on the subtype of G-protein coupled receptors involved in signaling (49) . For example, in human embryonic kidney cells, PGE 2 has been reported to be involved in phosphorylation of ERK1/2 through a PI3K-dependent mechanism (49) . Similarly, in squamous cell carcinoma, PGE 2 initiates a cascade of events involving both c-src and PKA to activate EGFR (25) . However, in our study, PGE 2 -induced EGFR activation did not require PKA or c-src, as PKA and c-src inhibitors did not affect PGE 2 -induced phosphorylation of EGFR in normal PMKs. PGE 2 -induced ERK1/2 phosphorylation was blocked by the PI3K inhibitor, suggesting that in normal PMKs, PGE 2 -induced activation of ERK1/2 was PI3K dependent.
Furthermore, in this study, we also found that PGE 2 induced c-src activation and this c-src seems to be downstream of the EGFR. Several reports suggest that c-src signaling plays a role in skin tumor promotion (51) . Recently, transgenic mice overexpressing either WT c-src or a constitutively active form developed significantly greater epidermal hyperplasia than nontransgenic mice after TPA treatment (52, 53) . Thus, during skin tumor promotion, it is possible that PGE 2 -induced c-src activation contributes to PGE 2 -stimulated keratinocyte proliferation.
Next, we showed that PGE 2 increases cyclin D1 and VEGF expression in PMKs and in mouse skin and this increased expression was significantly inhibited by EGFR, ERK1/2, and PKA inhibitors. In addition, our results showed that PGE 2 induces activation of Akt and this activated Akt is involved in PGE 2 -induced cyclin D1 and VEGF expression, as expression was inhibited by wortmannin, an Akt pathway inhibitor. It has been suggested that hyperactivated Akt can promote cell proliferation, possibly through down-regulation of p27, as well as up-regulation of cyclin D1 (54) . Furthermore, studies revealed that activated Akt and MAPKs can activate several transcription factors, including CREB, AP-1, and NF-nB (46, (55) (56) (57) , which bind to the regulatory elements of the promoter regions of genes such as cyclin D1 and VEGF (58, 59) . The up-regulation of cyclin D1 and VEGF play an essential role in mouse skin carcinogenesis as cyclin D1 -deficient mice showed resistance to tumor development (60) and transgenic mice overexpressing VEGF showed accelerated tumor development (61) . Moreover, studies have suggested that cyclin D1 can be induced by growth factors and TPA through activation of various signaling pathways including Ras/MAPKs, PI3K/Akt, AP-1, CREB, and NF-nB (62, 63) . Similarly, reports suggest that VEGF is a potent regulator of angiogenesis and Ha-rasmediated EGFR activation and Akt signaling are involved in the regulation of skin angiogenesis (64, 65) . In skin carcinogenesis, angiogenesis occurs very early in papilloma development, establishing blood vessel networks as tumors progress (65) . Furthermore, we have previously showed that overexpression of the EP2 receptor resulted in induction of vascularization and enhancement of VEGF expression after PGE 2 treatment (66).
It is well known that cAMP regulates a variety of biological events, such as cell type -dependent proliferation and differentiation, and that most of its effects are mediated through the cAMP-dependent PKA/CREB pathway (33, 35, 67) . In this study, PGE 2 induced higher levels of cAMP and increased CREB phosphorylation in PMKs and skin. Similarly, the cAMP/PKA pathway was shown to be involved in the growth of colon cancer cells via induction of amphiregulin, an EGFR ligand (68) . Thus, PGE 2 -induced proliferation of keratinocytes was associated with the increased cAMP levels and activated CREB. Moreover, recently, it has been shown that TPA increased the levels of cAMP in PMKs and in vivo and promoted the activation of the CREB transcription factor (33) . Thus, these data further support our hypothesis that some common signaling pathways are used by TPA and PGE 2 to regulate keratinocyte proliferation in vitro and in vivo.
In summary, there are several noteworthy findings from our study. First, exogenous or endogenous PGE 2 can induce keratinocyte proliferation both in vitro and in vivo. Second, this study provides evidence for PGE 2 -induced activation of CREB, NF-nB, and AP-1 in PMKs and in mouse skin. Third, PGE 2 can activate multiple signaling pathways, including cAMP/PKA, EGFR, Ras-MAPK, and PI3K/AKT, in vitro and in vivo that regulate activation of CREB, NF-nB, and AP-1, as illustrated in Fig. 6D . These findings suggest that PGE 2 induces keratinocyte proliferation and likely promotes tumorigenesis as well, through a number of interrelated signaling pathways. Additional studies are needed to determine which E-prostanoid receptor(s) is responsible for PGE 2 activation of the various signaling pathways. Given the recently reported side effects associated with currently available COX-2 inhibitors (27), our findings suggest that an understanding of PGE 2 signal transduction pathways that are critical for tumor development and growth may offer potential new targets for cancer prevention or intervention.
Materials and Methods
Animals
The K14.COX-2 transgenic mice on a FVB background were generated and maintained as previously described (36) . WT FVB mice were purchased from Harlan, and females were used in experiments at 6 to 8 weeks of age. All mice were maintained at Science Park and housed in an air-conditioned animal facility that is accredited by the Association for Assessment and Accreditation of Lab Animal Care.
Cell Culture
PMKs from newborn WT mice were prepared as described by Yuspa et al. (69) . Briefly, 1-to 2-day-old newborns were euthanized and washed in 70% ethanol. The skin was stripped off and floated on 0.25% trypsin overnight at 4jC. The epidermis was separated from the dermis and chopped in Waymouth's medium (Life Technologies) containing 1.2 mmol/L calcium and 10% fetal bovine serum. The cells were allowed to attach at 37jC in 5% CO 2 for 2.5 h, and the medium was then replaced with serum-free Keratinocyte Growth Medium-2 (Cambrex BioScience) containing 0.03 mmol/L calcium.
Cell Proliferation
Two approaches were used to measure keratinocyte proliferation in vitro and in vivo. To show the effect of PGE 2 -and pathway-specific inhibitors on induction of keratinocyte proliferation in vitro, PMKs from WT mice, grown to f80% to 85% confluence in six-well plates, were treated with vehicle or with To assess the effect of PGE 2 on keratinocyte proliferation in vivo, 6-and 8-wk-old WT mice were shaved 2 d before treatment with acetone or PGE 2 (30 Ag/200 AL acetone); 6-to 8-wk-old vehicle-treated K14.COX-2 transgenic mice were also used. After 18 h of treatment, mice were euthanized and dorsal skins were removed, fixed in formalin, and processed for paraffin embedding and immunohistochemical staining with M724 antibody against Ki-67 (DAKO) by the Histology Core of the Science Park-Research Division. Ki-67 -positive basal cells were counted in three to five randomly selected areas of each skin section and the mean percentage of Ki-67 -positive cells and SD of each treatment group were determined.
cAMP Analysis cAMP measurement was carried out using an enzyme immunoassay kit from Perkin-Elmer Life Sciences using the nonacetylation method outlined in the manufacturer's instructions. To determine the inhibitory effect of the adenylate cyclase inhibitor SQ 22,536 (Sigma Chemical Co.) on cAMP levels, cultures were treated with 10 Amol/L SQ 22,536 30 min before PGE 2 treatment. The calculation of cAMP concentrations (pmol/mg protein) was based on the standard curve for each experiment.
Western Blotting
For Western blotting, 2.5 Â 10 6 PMKs were cultured for 24 h in serum-free medium in 60-mm dishes. Cells were treated with specific inhibitors for EGFR kinase (AG1478, 10 Amol/L) or MEK1/2 (PD98059, 10 Amol/L), PKA (H-89, 10 Amol/L), or 100 nmol/L wortmannin for 30 min before stimulation with 10 Amol/L PGE 2 (for the time periods specified in the figure legends) or with vehicle. All the inhibitors were purchased from Calbiochem. After stimulation with PGE 2 , cells were scraped and suspended in radioimmunoprecipitation assay lysis buffer [150 mmol/L NaCl, 50 mmol/L Tris/HCl (pH 7.4), 1 mmol/L EDTA, 0.1% SDS, 1.0% Triton X-100, 0.25% deoxycholate] plus protease and phosphatase inhibitors and centrifuged for 10 min at 14,000 rpm. The supernatant was used immediately for protein determination using a BCA Kit. For p-ERK1/2, p-p38, p-JNK/SAPK, p-Akt, p-src, and p-CREB, proteins were resolved on a 10% SDS/PAGE gel, under reducing conditions. Separated proteins were electrophoretically transferred to polyvinylidene difluoride membranes and blocked with 5% nonfat dry milk or bovine serum albumin in TBS containing 0.1% Tween 20 (TBST) for 1 h at room temperature. Blots were then incubated with specific primary antibodies for p-CREB, p-Akt ( Blots were washed with TBST and subjected to corresponding horseradish peroxidase -conjugated secondary antibodies antimouse or anti-rabbit IgG (Amersham) or anti-goat IgG (Santa Cruz Biotechnology). Blots were washed with TBST and proteins were detected with a chemiluminescence kit (Pierce). The membranes were stripped in 62.5 mmol/L Tris-HCl (pH 6.8), 100 mmol/L 2-mercaptoethanol, 2% SDS at 68jC for 30 min, and reprobed with antibodies to total Akt, c-src, p38, JNK, or CREB (Cell Signaling), ERK1/2, EGFR, or actin (Santa Cruz Biotechnology), respectively. Blots were analyzed by densitometry using a Kodak Image Station, and normalized to total EGFR, total Akt, total ERK1/2, total p38, total CREB, or actin.
Northern Blot Analysis
Total RNA was extracted from PGE 2 -or vehicle-treated primary cell cultures and/or whole skins of mice with Trireagent (Molecular Research Center, Inc.) following the manufacturer's protocol. Ten micrograms of total RNA from each sample were separated on 1% agarose/6% formaldehyde gel, and then transferred to nylon membranes. [ 32 P]dCTPlabeled cDNA probe for cyclin D1 or VEGF was hybridized to the blots at 65jC for 16 h. The blots were then washed to a final stringency of 0.1% SDS/0.1Â NaCl/sodium citrate solution (where 1Â is 0.15 mol/L NaCl/15 mmol/L sodium citrate) at 60jC and exposed to X-ray film at À80jC. The blots were stripped and reprobed with glyceraldehyde-3-phosphate dehydrogenase cDNA as a loading control. Blots were analyzed by densitometry using a Kodak Image Station, and the values were normalized to glyceraldehyde-3-phosphate dehydrogenase.
Preparation of Nuclear Extracts
Nuclear extracts were prepared as described previously (70), with the following modifications. In brief, PMKs were incubated in serum-free medium for 24 h followed by the desired treatments, washed with cold PBS twice, and scraped from the plates in ice-cold lysis buffer [10 mmol/L HEPES (pH 7.9), 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1 mmol/L DTT, 1 mmol/L phenylmethylsulfonyl fluoride, 2 Ag/mL leupeptin, 2 Ag/mL aprotinin, and 1.0% NP40] and left on ice for 40 min. After vigorous vortexing for 10 s, homogenates were centrifuged at 14,000 rpm for 30 s. The resulting supernatant was collected as cytosolic extract. The pellet was then resuspended in nuclear extraction buffer [20 mmol/L HEPES (pH 7.9), 400 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L DTT, and 1 mmol/L phenylmethylsulfonyl fluoride], vigorously rocked at 4jC for 45 min, and centrifuged for 5 min at 14,000 rpm. The supernatant (nuclear extract) thus obtained was used to assay the DNA-binding activity of CREB, AP-1, and NF-nB.
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assays were done by standard techniques. Briefly, CREB-, AP-1 -, or NF-nB -specific oligonucleotides (5 pmol) were end labeled with [g-32 P]ATP (3,000 Ci/mmol) using T4 polynucleotide kinase (Promega). Labeled double-stranded oligo probes were separated from free [g-32 P]ATP using G-25 Sephadex column. The consensus sequences of the oligonucleotides used were 5 ¶-CTCTCTC-TGACGTCAGCCAATCGA-3 ¶ and 5 ¶-TCGATTGGCT-GACGTCAGAGAGAG-3 ¶ for CREB, 5 ¶-AGCTTCATGAGT-C A G C C G G AT C -3 ¶ a n d 5 ¶-G AT C C G G C T G A C T C -ATGAAGCT-3 ¶ for AP-1 and 5 ¶-AGTTGAGGGGACTTTCC-CAGGC-3 ¶ and 5 ¶-GCCTGGGAAAGTCCCCTCAACT-3 ¶ for NF-nB. Four micrograms of protein from nuclear extracts were first incubated with 10 AL of 5Â gel shift binding buffer containing 20% glycerol, 5 mmol/L MgCl 2 , 2.5 mmol/L EDTA, 2.5 mmol/L DTT, 250 mmol/L NaCl, 50 mmol/L Tris-HCl, and 1 Ag/AL poly(dI-dC):poly(dI-dC) and then with g-32 P endlabeled consensus oligonucleotide for 45 min at 37jC. The DNA-protein complexes thus formed were resolved on 6% nondenaturing polyacrylamide gels. Gels were then dried and subjected to autoradiography at À80jC.
Transient Transfections and Luciferase Assays
PMKs (1 Â 10 6 per well) were plated in six-well plates and grown to f60% confluence. Following replacement of medium with fresh Keratinocyte Growth Medium-2, cells were transfected with plasmid(s) as indicated below, using FuGENE6 transfection reagent (Roche Diagnostics) as described by the manufacturer. To test the effect of PGE 2 on cyclin D1 and VEGF promoter activity, in one set of experiments, each well was transfected with 1 Ag of a luciferase reporter construct driven by a 1,745 bp cyclin D1 promoter (a kind gift from Dr. Chris Albanese, The Albert Einstein Cancer Center, New York, NY). In another set of experiments, PMKs were transfected with 1 Ag of a luciferase reporter construct driven by a 1,336-bp VEGF promoter (a kind gift from Dr. Lee M. Ellis, M. D. Anderson Cancer Center, Houston, TX). All cultures were cotransfected with CMV-h-galactosidase (h-gal) plasmid (Clontech Laboratories, Inc.) to control for transfection efficiency. After 16 h, transfected cells were treated for 24 h with either vehicle or PGE 2 . Luciferase activity was measured using the Luciferase Assay System (Promega), and h-gal activity was measured using the Galacto-Light assay kit (Tropix). Light from either assay was detected by a luminometer (Tropix). The protein concentration of each cell lysate was quantified by the BCA protein assay. Luciferase activity was normalized to h-gal activity and protein concentration and then expressed as relative luciferase activity.
Ras Activation Assays
Ras activity was measured using a Ras Activation Assay Kit (Upstate Biotechnology, Inc.) following the manufacturer's instructions. In brief, PMKs were stimulated with PGE 2 at the indicated concentrations and for the indicated times. Cells were washed twice with ice-cold PBS and lysed in Mg 2+ lysis/ washing buffer (from kit) containing protease inhibitor cocktail tablets (Roche) for 15 min at 4jC. Cell lysates were centrifuged at 1,000 Â g for 20 min. The protein concentrations of the supernatants were then determined with the BCA Kit. Equal amounts of sample (500 Ag) were immediately affinity precipitated using 20 Ag of recombinant glutathione S-transferase -c-Raf-1 Ras binding domain fusion proteinconjugated glutathione-Sepharose beads (Raf-1 RBD, agarose) provided with the assay kit for 1 h at 4jC. The precipitates were washed thrice with Mg 2+ lysis/washing buffer and eluted by boiling in 40 AL 2Â SDS-PAGE sample buffer. The proteins were separated on a 12% SDS-polyacrylamide gel and then immunoblotted with a pan-Ras antibody (supplied with the kit). To normalize the amount of GTP-bound Ras to total amount of Ras, equal volumes of cell lysate were also subjected to Western blot analysis using the pan-Ras antibody.
ChIP Assay
To detect the in vivo association of nuclear proteins with the cyclin D1 and VEGF promoters, ChIP assays were conducted using the protocol described by Upstate Biotechnology with some modifications. In brief, PMKs (1 Â 10 7 ) were serum starved for 24 h and then stimulated for 30 min with PGE 2 and protein-DNA complexes were fixed with 1% formaldehyde solution for 10 min at 37jC. The cells were washed twice with ice-cold PBS containing protease inhibitors and scraped into a conical tube, centrifuged for 5 min at 2,000 rpm, lysed in 200 AL of SDS buffer [1% SDS, 10 mmol/L EDTA, and 50 mmol/LTris-HCl (pH 8.1)], and placed on ice for 10 min. The cell lysate was then sonicated to generate 200-to 1,000-bp DNA fragments. After centrifugation, the cleared supernatant was diluted 10-fold with ChIP buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mmol/L EDTA, 16.7 mmol/L Tris-HCl, 16.7 mmol/L NaCl, and protease inhibitors (pH 8.0)]. Chromatin solutions were incubated with 1.5 Ag of CREB or c-Jun (Cell Signaling) or p65, c-Fos (Santa Cruz Biotechnology) antibody at 4jC, and immune complexes were mixed with 60 AL of salmon sperm DNA/protein A/G agarose slurry (Upstate Biotechnology) for 1 h. Normal mouse IgG (Santa Cruz Biotechnology) was used instead of specific antibody in the negative control. The protein A/G agarose-antibody-chromatin complex was pelleted by centrifugation at 2,000 rpm for 1 min at 4jC. The pellet was extensively washed and eluted by resuspension in fresh elution buffer (1% SDS and 50 mmol/L NaHCO 3 ). Twenty microliters of 5 mol/L NaCl were added to the supernatant, and the mixture was incubated at 65jC for 4 h to reverse histone-DNA crosslinking. The DNA fragments were purified using the phenol/ chloroform extraction method and dissolved in 20 AL water. Each sample (5 AL) was used as a template for PCR amplification. Cyclin D1 oligonucleotide sequence for PCR primers were 5 ¶-CCTCAACGAAGCCAATCAAG-3 ¶ and 5 ¶-CAG-TATCCCCCTCCTCCACT-3 ¶. This primer set encompasses the cyclin D1 promoter segment that includes the CRE and TRE binding sites. Other cyclin D1 oligonucleotide sequences for PCR primers were 5 ¶-CCGGCTTTGATCTCTGCTTA-3 ¶ and 5 ¶-GCTGTACTGCCGGTCTCC-3 ¶. This primer set encompasses the cyclin D1 promoter segment that includes the AP-1 binding site. VEGF oligonucleotide sequences for PCR primers were 5 ¶-TGTGTCAATGTGAGTGCGTGC-3 ¶ and 5 ¶-GCGGTGGAAGAAAAAGAGGAAATC-3 ¶. These primers amplify the VEGF promoter segment that includes the CRE and TRE binding site. Other VEGF oligonucleotide sequences for PCR primers were 5 ¶-GCAGCTGGCCTACCTACCTT-3 ¶ and 5 ¶-ACTGAGAACGGGAAGTGGAG-3 ¶. This primer set encompasses the VEGF promoter surrounding the AP-1 binding site. PCR mixtures were amplified for one cycle at 94jC for 5 min followed by 35 cycles at 94jC 30 s, 60jC for 30 s, and 72jC for 45 s, and then subjected to final elongation at 72jC for 10 min. PCR products were run on 2% agarose gel and analyzed by ethidium bromide staining. All ChIP assays were done at least thrice with similar results.
Statistical Analysis
Data are shown as the mean F SD. Statistical differences between means were determined by one-way ANOVA, using SPSS 10 (SPSS Mac V.10, SPSS).
